Immunohistochemical analysis of the expression of TNF-alpha, TGF-beta, and caspase-3 in subcutaneous tissue of patients with HIV Lipodystrophy Syndrome

Microbial Pathogenesis

Volumn 67-68, Issue 1, 2014, Pages 41-47

  de Souza Dantas Oliveira, Sandro Henrique ^a   de Souza Aarão, Tinara Leila ^a   da Silva Barbosa, Leonardo ^a   Souza LisbÔa, Paulo Guilherme ^a   Tavares Dutra, Claudia Daniele ^a   Margalho Sousa, Lorena ^a   Simões Quaresma, Juarez AntÔnio ^a   Feio Libonati, Rosana Maria ^a  

^a FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

Caspase 3; Etiology; HIV Lipodystrophy Syndrome; Transforming Growth factor beta; Tumor necrosis factor alpha

Indexed keywords

ANTIRETROVIRUS AGENT; BIOTIN; CASPASE 3; CYTOKINE; PEROXIDASE; STREPTAVIDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ADULT; APOPTOSIS; ARTICLE; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEEDBACK SYSTEM; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; LIPOATROPHY; LIPOHYPERTROPHY; MALE; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE;

CASPASE 3; ETIOLOGY; HIV LIPODYSTROPHY SYNDROME; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APOPTOSIS; CASPASE 3; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; IMMUNOCHEMISTRY; MALE; MIDDLE AGED; SUBCUTANEOUS TISSUE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896038057     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2014.02.004     Document Type: Article

References (34)

1. UNAIDS Treatment 2015 2012, UNAIDS, Geneva, [accessed Aug 2013]. Available from:. http://www.unaids.org/en/resources/publications/2013/.
2. Stankov M.V., Behrens G.M. Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients. Curr Pharm Des 2010 Oct, 16(30):3361-3371. 10.2174/138161210793563473.
3. Capeau J., Caron M., Vigouroux C., Cervera P., Kim M., Maachi M., et al. Les lipodystrophies secondaires aux traitements antirétroviraux de l'infection par le VIH. Médecine-Sciences 2006, 22(5):531-536.
4. Mallewa J.E., Wilkins E., Vilar J., Mallewa M., Doran D., Back D., et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. JAntimicrob Chemother 2008 Oct, 62(4):648-660. 10.1093/jac/dkn251.
5. Samaras K., Wand H., Law M., Emery S., Cooper D.A., Carr A. Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism. Curr HIV Res 2009 Jul, 7(4):454-461.
6. Sattler F.R. Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Top HIV Med 2008 Oct-Nov, 16(4):127-133.
7. Alencastro P.R., Wolff F.H., Schuelter-Treviso F., Ikeda M.L., Brandão A.B.M., Barcellos N.T., et al. Characteristics associated to lipodistrophy syndrome among HIV-infected patients naive and on antiretroviral treatment. JAIDS Clin Res 2012, 3(9):1-9.
8. Pirmohamed M. Clinical management of HIV-associated lipodystrophy. CurrOpin Lipidol 2009 Aug, 20(4):309-314. 10.1097/MOL.0b013e32832d3bb1.
9. Johnson J.A., Albu J.B., Engelson E.S., Fried S.K., Inada Y., Ionescu G., et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004 Feb, 286(2):E261-E271. 10.1152/ajpendo.00056.2003.
10. Ledru E., Christeff N., Patey O., de Truchis P., Melchior J.C., Gougeon M.L. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associtated lipodystrophy syndrome. Blood 2000 May, 95(10):3191-3198.
11. Ross A.C., Armentrout R., O'Riordan M.A., Storer N., Rizk N., Harrill D., et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. JAcquir Immune Defic Syndr 2008 Dec 15, 49(5):499-506. 10.1097/QAI.0b013e318189a794.
12. Milinkovic A., Martinez E. Current perspectives on HIV-associated lipodystrophy syndrome. JAntimicrob Chemother 2005, 56:6-9. 10.1093/jac/dki165.
13. Durnin J.V., Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974 Jul, 32(1):77-97.
14. Caron M., Vigouroux C., Bastard J.P., Capeau J. Adipocyte dysfunction in response to antiretroviral therapy: clinical, tissue and in-vitro studies. Curr Opin HIV AIDS 2007, 2(4):268-273. 10.1097/COH.0b013e32814b1638.
15. Vidal F., Domingo P., Villarroya F., Giralt M., López-Dupla M., Gutiérrez M., et al. Adipogenic/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: significant alterations despite low viral burden. JAcquir Immune Defic Syndr 2012 Oct, 61(2):131-137.
16. Galli M., Cozzi-Lepri A., Ridolfo A.L., Gervasoni C., Ravasio L., Corsico L., et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy. ArchIntern Med 2002, 162(22):2621-2628. 10.1001/archinte.162.22.2621.
17. Robles D.T., Olson J.M., Colven R.M. Lipodystrophy in HIV 2011 Jul, Medscape, [accessed Oct 2012]. Available from:. http://emedicine.medscape.com/article/1082199-overview.
18. Andany N., Raboud J.M., Walmsley S., Diong C., Rourke S.B., Rueda S., et al. Ethinicity and gender differences in lipodystrophy of HIV-positive taking antiretroviral therapy in Ontario. Canada. HIV Clin Trials 2011 Mar-Apr, 12(2):89-103. 10.1310/hct1202-89.
19. Abbas A.K., Lichtman A.H., Abbas Pillai S. Cellular and molecular immunology 2011, Saunders Co, Philadelphia. 7th ed.
20. Green A., Rumberger J.M., Stuart C.A., Ruhoff M.S. Stimulation of lipolysis by tumor necrosis factor-α in 3T3-L1 adipocytes is glucose dependent - implications for long-term regulation of lipolysis. Diabetes 2004 Jan, 53(1):74-81. 10.2337/diabetes.53.1.74.
21. Souza S.C., Palmer H.J., Kang Y.H., Yamamoto M.T., Muliro K.V., Paulson K.E., et al. TNF-α induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes. JCell Biochem 2003 Aug, 89(6):1077-1086. 10.1002/jcb.10565.
22. Tchoukalova Y.D., Koutsari C., Votruba S.B., Tchkonia T., Giorgadze N., Thomou T., et al. Sex- and depot-dependent differences in adipogenesis in normal weight humans. Obesity (Silver Spring) 2010 Oct, 18(10):1875-1880. 10.1038/oby.2010.56.
23. Lindegaard B., Keller P., Bruunsgaard H., Gerstoft J., Pedersen B.K. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 2004, 135(2):273-279. 10.1111/j.1365-2249.2004.02367.x.
24. Jan V., Cervera P., Maachi M., Baudrimont M., Kim M., Vidal H., et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004 Aug, 9(4):555-564.
25. Lihn A.S., Richelsen B., Pedersen S.B., Haugaard S.B., Rathje G.S., Madsbad S., et al. Increased expression of TNF-, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003 Nov, 285(5):E1072-E1080. 10.1152/ajpendo.00206.2003.
26. Mynarcik D.C., Mcnurlan M.A., Steigbigel R.T., Fuhrer J., Gelato M.C. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. JAcquir Immune Defic Syndr 2000 Dec, 25(4):312-321.
27. Flint O.P., Noor M.A., Hruz P.W., Hylemon P.B., Yarasheski K., Kotler D.P., et al. The role of protease inhibitors in the pathogenesis of HIV-associates lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol 2009 Jan, 37(1):65-77. 10.1177/0192623308327119.
28. Gimeno R.E., Klaman L.D. Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol 2005 Apr, 5(2):122-128.
29. Kershaw E.E., Flie J.S. Adipose tissue as an endocrine organ. JClin Endocrinol Metab 2004 Jun, 89(6):2548-2556. 10.1210/jc.2004-0395.
30. Domingo P., Matias-Guiu X., Pujol R.M., Francia E., Lagarda E., Sambeat M.A., et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999 Nov, 13(16):2261-2267.
31. Good M., Newell F.M., Haupt L.M., Whitehead J.P., Hutley L.J., Prins J.B. TNF and TNF receptor expression and insulin sensitivity in humano mental and subcutaneous adipose tissue-influence of BMI and adipose distribution. Diab Vasc Dis Res 2006 May, 3(1):26-33. 10.3132/dvdr.2006.003.
32. Domingo P., Vidal F., Domingo J.C., Veloso S., Sambeat M.A., Torres F., et al. Tumor necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 2005 Dec, 35(12):771-780. 10.1111/j.1365-2362.2005.01576.x.
33. Lauber K., Bohn E., Kröeber S.M., Xiao Y., Blumenthal S.G., Lindemann R.K., et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003 Jun, 113(6):717-730. 10.1016/S0092-8674(03)00422-7.
34. Caron M., Vigouroux C., Bastard J.P., Capeau J. Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: alteration of the PPARγ-dependent pathways. PPAR Res 2009, 2009:1-8. 10.1155/2009/507141.